Five Star Equities releases regular market updates so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at www.FiveStarEquities.com and get exclusive access to our numerous stock reports.
Arca Biopharma Inc. (NASDAQ: ABIO) shares jumped 26.11 percent to close at $2.27 a share Wednesday. The stock traded between $2.15 and $2.54 on volume of 16.24 million shares traded. The company announced that the FDA has accepted the application for the planned companion diagnostic test for Gencaro. Shares of Arca Biopharma have fallen approximately 5.0 percent in the past year.
Get more information on Arca Biopharma and free access to the in-depth equity report at: www.FiveStarEquities.com/ABIO
ArthroCare Corporation (NASDAQ: ARTC) shares jumped 14.76 percent to close at $46.57 a share Wednesday. The stock traded between $44.95 and $49.94 on volume 1.47 million shares traded. The company announced that it will pay a $30.0 million fine to end an investigation by the U.S. Department of Justice. Shares of ArthroCare have gained approximately 30.0 percent in the past year.
Get more information on ArthroCare free access to the in-depth equity report at: www.FiveStarEquities.com/ARTC
IMRIS Inc. (NASDAQ: IMRS) shares surged 40.38 percent to close at $2.19 a share Wednesday. The stock traded between $1.52 and $2.24 on volume 1.95 million shares traded. The company announced that nearly 13,000 patients have been treated using intraoperative MRI since 2005. Shares of IMRIS have fallen approximately 40.0 percent in the past year.
Get more information on IMRIS and free access to the in-depth equity report at: www.FiveStarEquities.com/IMRS
Oramed Pharmaceuticals, Inc. (NASDAQ: ORMP) shares spiked 31.34 percent to close at $24.64 a share Wednesday. The stock traded between $19.82 and $25.15 on volume 1.92 million shares traded. MLV & Co. has recently initiated coverage on the company with a "buy" rating. Shares of Oramed Pharmaceuticals have gained over 200.0 percent in the past month.
Get more information on Oramed Pharmaceuticals and free access to the in-depth equity report at: www.FiveStarEquities.com/ORMP
Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Five Star Equities has no financial relationship with any company whose stock is mentioned in this release.
Contact: Five Star Equities [email protected]